Search results
Showing 16 to 22 of 22 results for gefitinib
Discontinued Reference number: GID-TAG422
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (TA403)
Evidence-based recommendations on ramucirumab (Cyramza) for locally advanced or metastatic non-small-cell lung cancer in adults who have had platinum-based chemotherapy.
Evidence-based recommendations on atezolizumab (Tecentriq) for locally advanced or metastatic non-small-cell lung cancer after chemotherapy in adults.
Discontinued Reference number: GID-TA11289
This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for people by ensuring that they get the most effective tests and treatments, and that they have access to suitable palliative care and follow-up.
This guidance has been updated and replaced by NICE technology appraisal guidance 374.
NICE has developed a medtech innovation briefing (MIB) on plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer .